Infectious Diseases in Obstetrics and Gynecology (Jan 2008)

Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates

  • Mei L. Castor,
  • Cynthia G. Whitney,
  • Kathryn Como-Sabetti,
  • Richard R. Facklam,
  • Patricia Ferrieri,
  • Joanne M. Bartkus,
  • Billie A. Juni,
  • Paul R. Cieslak,
  • Monica M. Farley,
  • Nellie B. Dumas,
  • Stephanie J. Schrag,
  • Ruth Lynfield

DOI
https://doi.org/10.1155/2008/727505
Journal volume & issue
Vol. 2008

Abstract

Read online

Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996—2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P<.001). Clindamycin resistance increased from 10.5% to 15.0% (X2 for trend 12.70; P<.001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X2 for trend 55.46; P<.001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.